Version June 2024
| Manifestation | Preferred treatment | Alternative treatment | Comments |
| Lymphocutaneous/cutaneous | Itr 200 mg/day | Itr 200 mg bid; or terbinafine 500 mg bid; or SSKI with increasing doses; or fluconazole 400 to 800 mg/day; or local hyperthermia | Treat for 2 to 4 weeks after lesions resolved |
| Osteoarticular | Itr 200 mg bid | Lipid AmB 3 to 5 mg/kg/day; or deoxycholate AmB 0.7 to 1 mg/kg/day | Switch to Itr after favorable response if AmB used; treat for a total of at least 12 months |
| Pulmonary | Lipid AmB 3 to 5 mg/kg/day, then Itr 200 mg bid; or Itr 200 mg bid | Deoxycholate AmB 0.7 to 1 mg/kg/d, then Itr 200 mg bid; surgical removal | Treat severe disease with an AmB formulation followed by Itr; treat less severe disease with Itr; treat for a total of at least 12 months |
| Meningitis | Lipid AmB 5 mg/kg/day, then Itr 200 mg bid | Deoxycholate AmB 0.7 to 1 mg/kg/day, then Itr 200 mg bid | Length of therapy with AmB not established, but therapy for at least 4 to 6 weeks is recommended; treat for a total of at least 12 months; may require long-term suppression with Itr |
| Disseminated | Lipid AmB 3 to 5 mg/kg/day, then Itr 200 mg bid | Deoxycholate AmB 0.7 to 1 mg/kg/day, then Itr 200 mg bid | Therapy with AmB should be continued until the patient shows objective evidence of improvement; treat for a total of at least 12 months; may require long-term suppression with Itr |
| Pregnant women | Lipid AmB 3 to 5 mg/kg/day or deoxycholate AmB 0.7-1.0 mg/kg/day for severe sporotrichosis; local hyperthermia for cutaneous disease | - | It is preferable to wait until after delivery to treat non-life-threatening forms of sporotrichosis |
| Children | Itr 6 to 10 mg/kg/day (400 mg/day maximum) for mild disease; deoxycholate AmB 0.7 mg/kg/day for severe disease | SSKI with increasing doses for mild disease | Treat severe disease with an AmB formulation followed by Itr |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
